John B. Moriarty - 23 Jun 2023 Form 3 Insider Report for Mirati Therapeutics, Inc.

Role: Chief Legal Officer
Signature: /s/ Betsy Gelfand, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 23 Jun 2023
Net transactions value: $0
Form type: 3
Filing time: 23 Jun 2023, 17:15:35 UTC
Previous filing: 02 Feb 2023
Next filing: 10 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MRTX	Common Stock						49,363	23 Jun 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MRTX	Employee Stock Option (Right to Buy)							23 Jun 2023	Common Stock	83,525	$45.88	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date, which was May 1, 2023.
F2	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was May 1, 2023 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.